Analysis of the Improvement of Inflammatory Factor Levels in Patients with Coronary Heart Disease and Hyperlipidemia Treated with Alirocumab and Atorvastatin

Zhuo Li; Yuan Liu

doi:10.26689/cr.v3i3.12184

Zhuo Li Qujing No.1 Hospital, The First Affiliated Hospital of Qujing Medical College, Qujing 655000, Yunnan, China
Yuan Liu Qujing Maternal and Child Health-care Hospital, Qujing 655000, Yunnan, China

DOI: https://doi.org/10.26689/cr.v3i3.12184

Keywords: Alirocumab, Atorvastatin, Coronary heart disease, Hyperlipidemia, Inflammatory factors

Abstract

Objective: To explore the efficacy of atorvastatin combined with alirocumab in the treatment of patients with coronary heart disease and hyperlipidemia. Methods: The study period was from June 2024 to June 2025. Patients with coronary heart disease and hyperlipidemia (n = 506) who received diagnosis and treatment in our hospital during this time period were included as the study subjects. The observation group and the control group were divided based on a random number table, with 253 patients in each group. Clinical treatment indicators were compared between the groups. Results: The total effective rate in the observation group was higher than that in the control group (P < 0.05). After treatment, there were significant differences in blood lipid levels, cardiac function indicators, coronary microcirculation, and inflammatory factor levels between the groups (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The combination of atorvastatin and alirocumab in the treatment of patients with coronary heart disease and hyperlipidemia is not only beneficial for improving cardiac function and blood lipid symptoms, but also has a prominent effect on coronary microcirculation and anti-inflammatory ability. The treatment is effective and safe, and can be promoted.

References

Yan W, Li B, 2025, Analysis of the Effect of Alirocumab Combined with Atorvastatin in the Treatment of Coronary Atherosclerotic Heart Disease with Hyperlipidemia. Big Doctor, 10(11): 71–73.

Li Y, 2025, The Effect of Alirocumab Combined with Hedan Capsule on Carotid Plaque in Coronary Heart Disease with Hyperlipidemia. Prevention and Treatment of Cardiovascular Diseases, 15(3): 45–48.

He J, 2025, Comparison of the Efficacy of Alirocumab and Evolocumab Combined with Atorvastatin in the Treatment of Coronary Heart Disease with Hyperlipidemia. Tianjin Pharmacy, 37(1): 86–89.

Yang W, Wang Q, Yu X, et al., 2024, Clinical Study of Alirocumab Combined with Atorvastatin in the Treatment of Coronary Heart Disease with Hyperlipidemia. Journal of Integrated Traditional Chinese and Western Medicine in Cardiovascular and Cerebrovascular Diseases, 22(15): 2808–2811.

Sun X, Zhao H, 2024, Research on the Value of Alirocumab Combined with Atorvastatin in the Treatment of Coronary Heart Disease with Hyperlipidemia. Chinese and Foreign Medical Treatment, 43(17): 85–87 + 99.

Chen L, 2023, The Effect of Alirocumab Combined with Atorvastatin in the Treatment of Coronary Heart Disease with Hyperlipidemia. Guide to Chinese Medicine, 21(35): 31–33.

Wang X, Ding S, Xu T, 2022, Evaluation of the Clinical Efficacy of Alirocumab in the Treatment of Hyperlipidemia with Carotid Plaque. Chinese Prescription Drug, 20(10): 107–109.